SOURCE: Edwards Lifesciences

Edwards Lifesciences

September 01, 2009 09:00 ET

Edwards Lifesciences Completes Sale of Hemofiltration Product Line

IRVINE, CA--(Marketwire - September 1, 2009) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that it has completed the sale of certain assets related to its hemofiltration product line to Baxter International Inc. (NYSE: BAX), consistent with the previously announced terms of the agreement.

"The completion of this transaction allows us to better focus resources on our strategic initiatives while benefitting Edwards' hemofiltration employees, products and customers," said Carlyn D. Solomon, Edwards' corporate vice president, Critical Care and Vascular.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring, with more than five decades of experience in partnering with clinicians to develop life-saving innovations. Headquartered in Irvine, Calif., Edwards treats advanced cardiovascular disease with its market-leading heart valve therapies, and critical care and vascular technologies, which are sold in approximately 100 countries. The company's global brands include Carpentier-Edwards, Cosgrove-Edwards, Edwards SAPIEN, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz. Additional company information can be found at

Edwards is a trademark of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.

Contact Information

  • Media Contact:
    Amanda Fowler

    Investor Contact:
    David K. Erickson